ArticleExperimental biology and medicine (Maywood, N.J.)2022
Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.
Rui Zhou, Hao-Chuan Ma, Yi-Hong Liu, Xian Chen, Xue-Song Chang, Ya-Dong Chen, Li-Rong Liu, Yong Li, Yan-Juan Zhu, Hai-Bo Zhang
Open access · greenAbstract read
In one paragraphArticle in Experimental biology and medicine (Maywood, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 1 institution in 1 country.
Rui ZhouThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.ORCID 0000-0003-2315-5569 Hao-Chuan MaThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Yi-Hong LiuDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Xian ChenThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Xue-Song ChangDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Ya-Dong ChenDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Li-Rong LiuDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Yong LiDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Yan-Juan ZhuThe Second Clinical Medical School of Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
Hai-Bo ZhangDepartment of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120, China.
Guangzhou University of Chinese Medicine · CN
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Despite significant advances in targeted and immune therapy for non-small cell lung cancer (NSCLC), effective therapies for wild-type epidermal growth factor receptor/anaplastic lymphoma kinase (
Indexed as
Carcinoma, Non-Small-Cell LungFerroptosisLung NeoplasmsAnaplastic Lymphoma KinaseB7-H1 AntigenBiomarkersErbB ReceptorsHumansImmune Checkpoint InhibitorsPrognosisTumor MicroenvironmentAnaplastic Lymphoma KinaseB7-H1 AntigenBiomarkersErbB ReceptorsImmune Checkpoint InhibitorsEGFR/ALKWTFerroptosisimmune microenvironmentlow PD-L1 expressionNSCLCprognosis
Identifiers
PMID35762414
PMCPMC9493762
OpenAlexW4283643969
What OpenQuestion holds
Textmetadata
Read underepoch 390